🔎 Trials Near Me

Utama › Kardiomiopati Hipertrofik › Massachusetts

Kajian klinikal Kardiomiopati Hipertrofik di Massachusetts

6 kajian untuk Kardiomiopati Hipertrofik sedang mencari peserta di lokasi di Massachusetts.

Bandar di Massachusetts

Teks kajian rasmi (Bahasa Inggeris)

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

  • Harvard (Massachusetts General Hospital), Boston
  • Harvard Medical School - Brigham and Women's Hospital (BWH), Boston
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT05489705

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

  • Tufts Medical Center, Boston
  • Boston Medical Center, Boston
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 50 ke atas · Semua jantina · Dikemas kini 4 Jun 2026 · NCT06034405

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

  • Imbria Investigational Site, Boston
  • Imbria Investigational Site, Burlington
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Mei 2026 · NCT07023614

A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

  • Boston Children's Hospital, Boston
Mengambil pesertaFasa 2
Umur 8 ke atas · Lelaki · Dikemas kini 4 Mei 2026 · NCT06092034

HCMR Re-Imaging Study

  • Brigham & Women's Hospital, Boston
  • Tufts Medical Center, Medford
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 65 · Semua jantina · Dikemas kini 18 Mac 2026 · NCT07054073

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

  • Analysis Group Inc., Boston
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Nov 2024 · NCT06551129

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.